Dimensional Fund Advisors LP grew its holdings in Anika Therapeutics Inc. (NASDAQ:ANIK) by 13.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 878,006 shares of the biotechnology company’s stock after purchasing an additional 106,307 shares during the period. Dimensional Fund Advisors LP owned about 5.99% of Anika Therapeutics worth $43,321,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. State of Alaska Department of Revenue raised its holdings in shares of Anika Therapeutics by 79.5% in the second quarter. State of Alaska Department of Revenue now owns 2,872 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 1,272 shares during the last quarter. Mason Street Advisors LLC raised its holdings in shares of Anika Therapeutics by 7.1% in the first quarter. Mason Street Advisors LLC now owns 3,423 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 228 shares during the last quarter. Victory Capital Management Inc. raised its holdings in shares of Anika Therapeutics by 68.4% in the first quarter. Victory Capital Management Inc. now owns 3,452 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 1,402 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its holdings in shares of Anika Therapeutics by 3.0% in the second quarter. Municipal Employees Retirement System of Michigan now owns 3,450 shares of the biotechnology company’s stock valued at $170,000 after purchasing an additional 100 shares during the last quarter. Finally, Envestnet Asset Management Inc. acquired a new stake in shares of Anika Therapeutics in the first quarter valued at approximately $204,000. Institutional investors own 84.44% of the company’s stock.

A number of research firms have recently issued reports on ANIK. Zacks Investment Research upgraded shares of Anika Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 2nd. BidaskClub upgraded shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, August 8th.

Shares of Anika Therapeutics Inc. (ANIK) opened at 59.59 on Wednesday. The firm has a market capitalization of $873.47 million, a P/E ratio of 26.47 and a beta of 1.66. Anika Therapeutics Inc. has a 12-month low of $41.38 and a 12-month high of $60.29. The stock has a 50 day moving average of $57.77 and a 200-day moving average of $50.64.

Anika Therapeutics (NASDAQ:ANIK) last issued its earnings results on Wednesday, July 26th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.32. Anika Therapeutics had a return on equity of 14.88% and a net margin of 30.44%. The company had revenue of $33.50 million for the quarter, compared to analysts’ expectations of $27.20 million. During the same period last year, the business earned $0.57 EPS. Anika Therapeutics’s quarterly revenue was up 25.9% compared to the same quarter last year. On average, equities research analysts predict that Anika Therapeutics Inc. will post $2.20 EPS for the current fiscal year.

In related news, CEO Charles H. Sherwood sold 63,799 shares of the stock in a transaction on Thursday, July 27th. The stock was sold at an average price of $50.79, for a total value of $3,240,351.21. Following the transaction, the chief executive officer now directly owns 174,705 shares in the company, valued at approximately $8,873,266.95. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Charles H. Sherwood sold 3,293 shares of the stock in a transaction on Monday, October 16th. The stock was sold at an average price of $60.04, for a total value of $197,711.72. The disclosure for this sale can be found here. Over the last quarter, insiders sold 102,435 shares of company stock worth $5,560,786. 6.57% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.watchlistnews.com/dimensional-fund-advisors-lp-acquires-106307-shares-of-anika-therapeutics-inc-anik/1653304.html.

About Anika Therapeutics

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.